Serina Therapeutics (SER) Change in Accured Expenses (2018 - 2025)

Serina Therapeutics has reported Change in Accured Expenses for 8 years, with the latest figure at -$168000.0 in Q4 2025.

• Quarterly Change in Accured Expenses fell 142.0% year-over-year to -$168000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $18000.0 (down 95.5% YoY) and the FY2025 annual result came in at $18000.0, down 95.5% from the prior year.
• Change in Accured Expenses fell to -$168000.0 in Q4 2025 per SER's latest filing, from $301000.0 in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $540000.0 in Q4 2021 and troughed at -$597000.0 in Q2 2024.
• A 5-year average of $10263.2 and a median of -$22000.0 in 2021 frame the typical range for Change in Accured Expenses.
• The sharpest annual moves came in 2023 and 2024: Change in Accured Expenses plunged 3800.0% in 2023, then surged 612.82% in 2024.
• Over 5 years, Change in Accured Expenses stood at $540000.0 in 2021, then plunged by 100.37% to -$2000.0 in 2022, then slumped by 3800.0% to -$78000.0 in 2023, then soared by 612.82% to $400000.0 in 2024, then plunged by 142.0% to -$168000.0 in 2025.
• According to Business Quant data, Change in Accured Expenses over the past three periods registered -$168000.0, $301000.0, and $273000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.